000			02289cam a2200325 a 4500
003			EG-GiCUC
008			180930s2018 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2018.Di.D
100	0		_aDiena Essam Aboelezz
245	1	0	_aDevelopment of gastroretentive sustained release drug delivery system for certain antibiotic and its in-vitro and in-vivo evaluation / _cDiena Essam Aboelezz ; Supervised Ahmed Hassan Elhafeey , Yousry Mahmoud Elsayed , Ibrahim Hassan Elsayed
246	1	5	_aتطوير نظام توصيل محتجز معويا لإطالة مفعول مضاد حيوى وتقييمه معمليا وحيويا
260			_aCairo : _bDiena Essam Aboelezz , _c2018
300			_a171 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aGastric retention is designed to prolong gastric residence time of oral controlled release dosage forms. Prolonged contact time of drug with the gastrointestinal mucosa, leads to higher bioavailability, and hence therapeutic efficacy, reduced time intervals for drug administration, potentially reduced dose size and thus improved patient compliance. It helps in sustaining drug delivery mainly for drugs that show site specific absorption from the stomach or the upper intestine. Ofloxacin is a broad-spectrum antimicrobial fluoroquinolone which has activity against a wide range of gram-negative and gram-positive microorganisms. It{u2019}s an off-white to pale yellow crystalline powder. Following oral administration, the bioavailability of ofloxacin in the tablet formulation is approximately 98%. Clearance of ofloxacin is reduced in patients with impaired renal function (creatinine clearance rate <50 mL/min), and dosage adjustment is necessary
530			_aIssued also as CD
653		4	_aGastroretentive
653		4	_aInvitro and invivo evaluation
653		4	_aOfloxacin
700	0		_aAhmed Hassan Elhafeey , _eSupervisor
700	0		_aIbrahim Hassan Elsayed , _eSupervisor
700	0		_aYousry Mahmoud Elsayed , _eSupervisor
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c67738 _d67738